NEW YORK, Oct. 22, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
CBS Corporation (: CBS)
Class Period: February 14, 2014 to July 27, 2018
Lead Plaintiff Deadline: October 26, 2018
According to the complaint, CBS Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) CBS executives, including the company’s Chairman and Chief Executive Officer, Leslie “Les” Moonves, had engaged in widespread workplace sexual harassment at CBS; (2) CBS’s enforcement of its own purported policies was inadequate to prevent the foregoing conduct; (3) the foregoing conduct, when revealed, would foreseeably subject CBS to heightened legal liability and impede the ability of key CBS personnel to execute the company’s business strategy; and (4) as a result, CBS’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the CBS lawsuit: http://www.kleinstocklaw.com/pslra-1/cbs-corporation-loss-form?wire=3
Cocrystal Pharma, Inc. (NASDAQCM: COCP)
Class Period: September 23, 2013 to September 7, 2018
Lead Plaintiff Deadline: November 19, 2018
Cocrystal Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the COCP lawsuit: http://www.kleinstocklaw.com/pslra-1/cocrystal-pharma-inc-formerly-biozone-pharmaceuticals-inc-loss-submission-form?wire=3
TG Therapeutics, Inc. (NASDAQCM: TGTX)
Class Period: June 4, 2018 to September 25, 2018
Lead Plaintiff Deadline: December 3, 2018
The complaint alleges TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.
Get additional information about the TGTX lawsuit: http://www.kleinstocklaw.com/pslra-1/tg-therapeutics-inc-loss-submission-form?wire=3
Trevena, Inc. (NASDAQGS: TRVN)
Class Period: May 2, 2016 to October 9, 2018
Lead Plaintiff Deadline: December 10, 2018
During the class period, Trevena, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the U.S. Food and Drug Administration ("FDA") had not agreed to key elements of the Company’s Phase 3 trial for oliceridine (TRV130); (ii) the FDA was unlikely to approve oliceridine (TRV130) based on the Company’s Phase 3 trial; and (iii) as a result, Trevena’s public statements were materially false and misleading at all relevant times.
Get additional information about the TRVN lawsuit: http://www.kleinstocklaw.com/pslra-1/trevena-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
